C K Kasper|L Parton - JoVE Visualize

Showing results (91-100 of 113) with videos related to

Pageof 12

Sort By:

Human Mutation|June 1, 2001

Frequency of recent retrotransposition events in the human factor IX geneX Li, W A Scaringe, K A Hill, et al.

Annals of Internal Medicine|February 1, 1984

Antibody to human T-cell leukemia virus membrane antigens, beta 2-microglobulin levels, and thymosin alpha 1 levels in hemophiliacs and their spousesJ K Kreiss, D N Lawrence, C K Kasper, et al.

Blood|June 1, 1986

Carrier detection in hemophilia A: a cooperative international study. II. The efficacy of a universal discriminantP P Green, P M Mannucci, E Briët, et al.

American Journal of Hematology|July 1, 1992

Coagulation factor IX: successful surgical experience with a purified factor IX concentrateJ C Goldsmith, C K Kasper, P M Blatt, et al.

Blood|June 1, 1986

Carrier detection in hemophilia A: a cooperative international study. I. The carrier phenotypeJ B Graham, C R Rizza, J Chediak, et al.

Thrombosis and Haemostasis|December 1, 1995

Molecular epidemiology of factor IX germline mutations in Mexican Hispanics: pattern of mutation and potential founder effectsE C Thorland, B G Weinshenker, J Z Liu, et al.

Archives of Internal Medicine|June 1, 1989

The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experienceD B Brettler, A D Forsberg, P H Levine, et al.

The American Journal of Medicine|March 1, 1986

Human T cell leukemia virus type III antibody, lymphadenopathy, and acquired immune deficiency syndrome in hemophiliac subjects. Results of a prospective studyJ K Kreiss, L W Kitchen, H E Prince, et al.

Human Mutation|May 26, 1998

Germline mutations in Peruvian patients with hemophilia B: pattern of mutation in AmerIndians is similar to the putative endogenous germline patternJ A Heit, E C Thorland, R P Ketterling, et al.

Blood|September 1, 1994

Effect of low- and intermediate-purity clotting factor therapy on progression of human immunodeficiency virus infection in congenital clotting disorders. Transfusion Safety Study GroupG F Gjerset, M C Pike, J W Mosley, et al.

Pageof 12

Showing results (91-100 of 113) with videos related to

Sort By:

Pageof 12

Human Mutation|June 1, 2001

Frequency of recent retrotransposition events in the human factor IX geneX Li, W A Scaringe, K A Hill, et al.

Annals of Internal Medicine|February 1, 1984

Antibody to human T-cell leukemia virus membrane antigens, beta 2-microglobulin levels, and thymosin alpha 1 levels in hemophiliacs and their spousesJ K Kreiss, D N Lawrence, C K Kasper, et al.

Blood|June 1, 1986

Carrier detection in hemophilia A: a cooperative international study. II. The efficacy of a universal discriminantP P Green, P M Mannucci, E Briët, et al.

American Journal of Hematology|July 1, 1992

Coagulation factor IX: successful surgical experience with a purified factor IX concentrateJ C Goldsmith, C K Kasper, P M Blatt, et al.

Blood|June 1, 1986

Carrier detection in hemophilia A: a cooperative international study. I. The carrier phenotypeJ B Graham, C R Rizza, J Chediak, et al.

Thrombosis and Haemostasis|December 1, 1995

Molecular epidemiology of factor IX germline mutations in Mexican Hispanics: pattern of mutation and potential founder effectsE C Thorland, B G Weinshenker, J Z Liu, et al.

Archives of Internal Medicine|June 1, 1989

The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experienceD B Brettler, A D Forsberg, P H Levine, et al.

The American Journal of Medicine|March 1, 1986

Human T cell leukemia virus type III antibody, lymphadenopathy, and acquired immune deficiency syndrome in hemophiliac subjects. Results of a prospective studyJ K Kreiss, L W Kitchen, H E Prince, et al.

Human Mutation|May 26, 1998

Germline mutations in Peruvian patients with hemophilia B: pattern of mutation in AmerIndians is similar to the putative endogenous germline patternJ A Heit, E C Thorland, R P Ketterling, et al.

Blood|September 1, 1994

Effect of low- and intermediate-purity clotting factor therapy on progression of human immunodeficiency virus infection in congenital clotting disorders. Transfusion Safety Study GroupG F Gjerset, M C Pike, J W Mosley, et al.

Pageof 12